What it's for (Indications)
- Risperidone, marketed under various brand names including Wizen, is an atypical antipsychotic medication primarily indicated for the management of several psychiatric conditions across different age groups.
- It is approved for the treatment of schizophrenia in adults and adolescents aged 13 to 17 years, providing effective control over positive symptoms like hallucinations and delusions, as well as negative symptoms such as apathy and social withdrawal, thereby improving overall functional outcomes.
- Furthermore, risperidone is indicated as monotherapy or as an adjunct to lithium or valproate for the acute treatment of manic or mixed episodes associated with Bipolar I disorder in adults, and for the acute treatment of manic or mixed episodes associated with Bipolar I disorder in children and adolescents aged 10 to 17 years.
- It also holds an important indication for the treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years, where it can help manage symptoms such as aggression, self-injurious behavior, temper tantrums, and rapidly changing moods.
- The therapeutic effects are thought to be mediated through a combination of dopamine D2 and serotonin 5-HT2A receptor antagonism, leading to improved thought processes, mood stabilization, and behavioral regulation in these complex disorders.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of risperidone (e.g., Wizen) must be individualized based on the patient's condition, age, tolerability, and clinical response, with careful titration to achieve optimal therapeutic effects while minimizing adverse reactions. For adults with schizophrenia, the usual starting dose is 0.5 mg to 1 mg orally twice daily, with gradual upward titration in increments of 0.5 mg to 1 mg per day to a target dose range of 2 mg to 8 mg per day, typically administered once or twice daily. Doses above 16 mg per day are generally not recommended due to increased risk of side effects. For manic or mixed episodes associated with Bipolar I disorder in adults, an initial dose of 2 mg once daily is common, with adjustments up to 6 mg per day. Pediatric dosing for schizophrenia (adolescents 13-17 years) and Bipolar I disorder (children/adolescents 10-17 years) often starts lower, around 0.5 mg daily, and is carefully titrated based on weight and response. For irritability associated with autistic disorder (children/adolescents 5-16 years), a very low starting dose of 0.25 mg once daily is typical, with slow titration up to 0.5 mg to 1.5 mg daily depending on weight and clinical response. Renal and hepatic impairment necessitate lower initial doses and slower titration schedules due to reduced drug clearance. Risperidone is available in oral tablets, an oral solution, and an extended-release injectable suspension for once-every-two-weeks administration, offering various options for patient adherence and convenience. |
Safety & Warnings
Common Side Effects
- Risperidone (e.
- g.
- , Wizen) is associated with a range of side effects, some of which are common and generally mild, while others can be serious and require immediate medical attention.
- Common adverse reactions reported across various indications include somnolence, insomnia, agitation, anxiety, headache, dizziness, fatigue, and gastrointestinal disturbances such as nausea, vomiting, and constipation.
- Extrapyramidal symptoms (EPS), including parkinsonism, akathisia, dystonia, and tremor, are dose-dependent and more prevalent at higher doses.
- Metabolic side effects are a significant concern, encompassing weight gain, dyslipidemia, and hyperglycemia, which can increase the risk of type 2 diabetes and cardiovascular disease.
- Hyperprolactinemia, leading to amenorrhea, galactorrhea, gynecomastia, and sexual dysfunction, is another frequent side effect due to risperidone's potent D2 receptor antagonism.
- Less common but serious adverse events include neuroleptic malignant syndrome (NMS), characterized by fever, muscle rigidity, altered mental status, and autonomic instability; tardive dyskinesia (TD), an irreversible movement disorder; orthostatic hypotension and syncope; seizures; cerebrovascular adverse events, particularly in elderly patients with dementia-related psychosis; and blood dyscrasias like neutropenia or agranulocytosis.
- Regular monitoring for these adverse effects is crucial during treatment.
Serious Warnings
- Black Box Warning: **WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS** Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Risperidone (e.g., Wizen) is not approved for the treatment of patients with dementia-related psychosis.
- Several significant warnings are associated with risperidone (e.
- g.
- , Wizen) that clinicians and patients must be aware of to ensure safe and effective use.
- Beyond the Black Box Warning, there is a risk of Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability; immediate discontinuation and supportive care are required if NMS is suspected.
- Tardive Dyskinesia (TD), a syndrome of potentially irreversible, involuntary dyskinetic movements, can develop, especially with long-term use; its risk and potential for irreversibility necessitate careful consideration, and treatment should be discontinued if signs of TD appear.
- Metabolic changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain, are common and require regular monitoring of blood glucose, lipid profiles, and body weight.
- Orthostatic hypotension and syncope can occur, particularly during initial dose titration, due to risperidone's alpha-adrenergic blocking activity, and caution is advised, especially in patients with known cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension.
- Hyperprolactinemia can lead to complications such as amenorrhea, galactorrhea, gynecomastia, and sexual dysfunction.
- Seizures have been reported, and risperidone should be used cautiously in patients with a history of seizures or conditions that lower the seizure threshold.
- The drug may impair judgment, thinking, or motor skills, cautioning patients about operating hazardous machinery, including automobiles.
- Suicidal ideation and behavior may occur, especially in young adults, necessitating close monitoring.
How it Works (Mechanism of Action)
Risperidone (e.g., Wizen) exerts its therapeutic effects primarily through a multifaceted interaction with various neurotransmitter receptors in the central nervous system, classifying it as an atypical antipsychotic. Its principal mechanism involves potent antagonism of serotonin 5-hydroxytryptamine type 2A (5-HT2A) receptors and dopamine D2 receptors. The combined blockade of these receptors is thought to be responsible for its efficacy in alleviating both positive symptoms (e.g., hallucinations, delusions) and negative symptoms (e.g., apathy, social withdrawal) of schizophrenia, as well as its mood-stabilizing effects in bipolar disorder. While D2 receptor blockade is crucial for antipsychotic efficacy, the concurrent 5-HT2A antagonism is believed to mitigate the extrapyramidal symptoms (EPS) often associated with conventional antipsychotics, which primarily block D2 receptors. In addition to these primary targets, risperidone also displays antagonism at alpha1-adrenergic and H1-histaminergic receptors. Blockade of alpha1-adrenergic receptors contributes to its potential for orthostatic hypotension, while H1-histaminergic receptor blockade can lead to somnolence and weight gain. The specific balance of these receptor affinities and the degree of antagonism contribute to risperidone's unique clinical profile, offering a broader range of therapeutic actions with a potentially more favorable side effect profile compared to older antipsychotics, while still requiring careful monitoring for metabolic and other adverse effects.
Commercial Brands (Alternatives)
No other brands found for this formula.